|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 5,856,348
US Patent 5,856,348, granted on January 5, 1999, covers a method for treating depressive disorders using oral administration of an antidepressant, specifically selective serotonin reuptake inhibitors (SSRIs). The patent primarily claims a method of use and composition involving known SSRIs, particularly fluoxetine, for treating depression with specific dosage regimens.
Claims Breakdown
- Claim 1: A method of treating a depressive disorder in a patient in need thereof, comprising administering a therapeutically effective amount of fluoxetine orally once daily, with the dose ranging from 10 to 80 mg/day.
- Claim 2: The method where the dose is between 20 to 60 mg/day.
- Claim 3: The treatment period spans from 3 to 12 weeks.
- Claim 4: The administration can be in a controlled-release form.
- Claim 5: The method also applies to treating other mood disorders such as obsessive-compulsive disorder (OCD) and panic disorder.
The claims emphasize the method of administration, dosing range, and treatment duration, focusing on specific indications (depressive and associated disorders) with fluoxetine as the agent.
Scope of the Patent
The patent provides protection for:
- Use of fluoxetine in specified dosage regimens for depression.
- Treatment durations between 3 to 12 weeks.
- Oral administration formats, including controlled-release formulations.
- Extension of application to related mental health conditions (OCD, panic disorder).
The broadest claims (Claim 1) cover any effective oral daily dose of fluoxetine within the specified range for depression treatment, providing a wide scope for formulation and dosing.
Patent Landscape Analysis
1. Patent Family and Related Patents
- The patent belongs to Eli Lilly and Company, which commercialized fluoxetine.
- It forms part of a patent family, including European (EP 0198479 B1), Japanese, and Canadian equivalents.
- The patent's priority date is October 2, 1990, with the US filing on September 29, 1994, providing protection until at least 2014, with possible extensions.
2. Competitor and Follow-up Patents
- Subsequent patents include combination therapies and new formulations of SSRIs.
- Competitors have filed patents aiming to around or improve upon the methods claimed in US 5,856,348, such as extended-release formulations, unique dosing schedules, or methods focusing on specific patient populations.
- Some patents (e.g., WO 1996/009829) claim similar indications with different compounds or delivery mechanisms.
3. Patent Expiry and Market Impact
- As of the patent's expiration in 2014, generic versions of fluoxetine entered the market in the US.
- The expiration allowed competitors to develop and market generic fluoxetine formulations without infringing the original patent.
- The patent’s scope limited the exclusivity of specific dosing regimens and formulations, which have now become standard practices.
4. Legal Status and Litigation
- The patent was litigated in the early 2000s, with some disputes over its validity based on prior art references.
- No recent litigation is associated with this patent, indicating its influence has waned post-expiry.
Implications for Drug Development and Investment
- The patent's claims supported Lilly’s patent estate during a critical period of market exclusivity for fluoxetine.
- The structured claims around dosing and treatment duration provided a degree of control, influencing prescribing practices.
- Post-expiry, market competition increased, prompting innovation in formulation and combination therapies rather than new indications.
Key Points Summary
- Patent Focus: Method of administering fluoxetine orally within specific dose ranges to treat depression and related disorders.
- Claims: Covering dosage (10-80 mg/day), treatment duration (3-12 weeks), and formulation types, including controlled-release forms.
- Scope: Broad for use and formulation; narrower for specific indications.
- Patent Landscape: Strong influence during patent life; post-expiry, generic competition accelerated.
- Legal Status: Valid until 2014, with subsequent landscape shifts toward generics and new formulations.
Key Takeaways
- US 5,856,348 established a proprietary method for administering fluoxetine in depression treatment within specified parameters.
- The claims were broad, covering dosing and formulations, influencing Lilly’s market position during patent life.
- Post-2014, patent expiration catalyzed generic fluoxetine development.
- The patent landscape features follow-up patents focusing on formulations and combination therapies.
- Understanding these claims aids in assessing freedom-to-operate and potential pathways for new antidepressant therapies.
FAQs
-
What is the primary innovation claimed in US 5,856,348?
The patent claims the method of treating depression with orally administered fluoxetine within a specific dose range and duration.
-
Has the patent been invalidated or revoked?
No, it was valid until its expiration in 2014. No recent legal actions challenge its validity.
-
How does this patent affect generic fluoxetine entry?
It restricted generic manufacturers from copying specific dosing and formulation claims until patent expiry.
-
Are there any current patents derived from or related to US 5,856,348?
Yes, post-expiry, multiple patents focus on formulations, delivery systems, and combination therapies.
-
Can the claims be extended to other SSRIs?
Not directly; this patent specifically covers fluoxetine. Similar claims for other SSRIs would require separate patent protection.
References
- US Patent 5,856,348. "Method of treatment using fluoxetine," issued Jan 5, 1999.
- European Patent EP 0198479 B1, related to fluoxetine formulations and methods.
- WHO, "Fluoxetine," The International Pharmacopoeia, 2018.
- FDA, "Fluoxetine Hydrochloride," Approved Drug Products, 1998.
More… ↓
⤷ Start Trial
|
